Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
GSK pens $750M deal for COPD-focused oligonucleotide in phase 1
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides.
James Waldron
Oct 28, 2025 6:45am
RNA biotech Soufflé rises with $200M and Big Pharma partners
Oct 7, 2025 3:30pm
US VC launches another biotech with China-licensed asset
Sep 17, 2025 10:30am
Novartis returns to Argo for $5B cardiovascular collab
Sep 3, 2025 9:15am
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
Regeneron posts phase 3 win, advancing push to muscle in on gMG
Aug 26, 2025 9:41am
